Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

2017 NCCN Annual Conference

Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Canc...

Lymphoma

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Leo I. Gordon, MD, of the Robert H. Lurie C...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Ket...

Gynecologic Cancers

ASCO Post

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer C...

Mar

Today In Oncology

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Related Videos

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

David G. Pfister, MD, on HPV and Head and Neck Cancer

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Updates From Selected Clinical Trials in Breast Cancer

FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine

Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn

FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

Pyrotinib/Capecitabine vs Lapatinib/Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab